Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

T Cell Activation Induces Synthesis of CD47 Proteoglycan Isoforms and Their Release in Extracellular Vesicles.

International journal of molecular sciences·2025

Same author

<i>CD47</i> and <i>IFT57</i> Are Colinear Genes That Are Highly Coexpressed in Most Cancers and Exhibit Parallel Cancer-Specific Correlations with Survival.

International journal of molecular sciences·2024

Same author

Differential regulation by CD47 and thrombospondin-1 of extramedullary erythropoiesis in mouse spleen.

eLife·2024

Same author

Endothelial cells release microvesicles that harbour multivesicular bodies and secrete exosomes.

Journal of extracellular biology·2024

Same author

Effects of a humanized CD47 antibody and recombinant SIRPα proteins on triple negative breast carcinoma stem cells.

Frontiers in cell and developmental biology·2024

Same author

Differential regulation by CD47 and thrombospondin-1 of extramedullary erythropoiesis in mouse spleen.

bioRxiv : the preprint server for biology·2023

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

CD47: a new target in cardiovascular therapy.

Jeff S Isenberg¹, David D Roberts, William A Frazier

¹Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Arteriosclerosis, Thrombosis, and Vascular Biology

|January 12, 2008

Summary

CD47 (integrin-associated protein) is a receptor that regulates vascular cell functions and immunity. New research shows it inhibits nitric oxide signaling, unifying its known roles in vascular physiology.

More Related Videos

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits

The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits

Published on: August 20, 2014

Related Experiment Videos

Last Updated: Jul 8, 2026

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits

The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits

Published on: August 20, 2014

Area of Science:

Vascular Biology
Immunology
Cell Signaling

Background:

CD47, also known as integrin-associated protein, is a cell surface receptor.
It plays roles in vascular cell migration, proliferation, survival, and immune regulation.
The interaction with thrombospondin-1 is crucial for its functions.

Purpose of the Study:

To explore the emerging paradigm of CD47 function in vascular physiology.
To highlight the role of CD47 in nitric oxide signaling.
To unify the understanding of CD47's diverse functions.

Main Methods:

Literature review and synthesis of existing research.
Analysis of studies investigating CD47-thrombospondin-1 interactions.
Examination of data on CD47's impact on nitric oxide pathways.

Main Results:

CD47 acts as a receptor for thrombospondin-1.
Thrombospondin-1 binding to CD47 inhibits nitric oxide signaling.
This inhibition affects vascular cell behavior and immune responses.

Conclusions:

The inhibition of nitric oxide signaling by thrombospondin-1 via CD47 provides a unifying mechanism for its functions.
This discovery enhances our understanding of CD47's critical role in vascular physiology.
Further research into this pathway could reveal new therapeutic targets.